Biotech HOLDRs BBH
-
Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's (VRTX) cystic fibrosis treatment - and because some investors are betting on deals ...
… Vertex's ( VRTX ) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech ( IBB ). Others include XBI , FBT and BBH . Post your comment!
-
BBH Core Select: 1st Quarter 2012
… months of the year, adding to an impressive rally that has resulted in a 24.40% total return over the last two quarters. BBH Core Select (“Core Select”) Class N rose by 10.88% in the first quarter and 20.16% over the last six months. On …
-
BBH Core Select: 1st Quarter 2012
After sorting through the details of last week's staggering $253 million verdict against Merck MRK, we've revised some of our assumptions for valuing the company and are adjusting our fair value estimate to $34 per share from $37 as a result. Previously, we had estimated the liability to Merck for
-
These Topnotch Funds Are Banking on Buffett
… management team, its consistent process, its A Stewardship Grade, and its below-category-average 0.75% expense ratio. BBH Core Select BBTRX Allocation to Berkshire Hathaway: 5.5% Warren Buffett's firm is this fund's top holding among the roughly …
-
Exciting Innovations In Nanotechnology On The Edge Of Coming To Commercial Markets
By Robert Hallberg : A lot of progress has been made in the field of biotechnology and biomedicine since the completion of the human genome projects in 2003. The completion of this project was a huge milestone, and it was supposed to usher in a new era of genetic medicine with new cures. But ...
-
Funds That Have Thrived on an Apple-Free Diet
… Mairs & Power and Oakmark, they each have relatively focused portfolios and aren't afraid to look different from the crowd. BBH Core Select BBTEX follows a similar playbook to Nygren's, using fundamental research to undercover higher-quality stocks …
-
Choosing The Right Biotech ETF Exposure
By Tom Lydon : Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash and the
-
PBE PowerShares Dynamic Biotech & Genome ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… 48%), and Market Vectors Biotech ETF BBH (0.35%). Both XBI and FBT offer equal ..... Another cap-weighted possibility is BBH , which holds a more concentrated portfolio ..... average market cap of $11.4 billion. BBH 's 0.35% expense ratio matches XBI …
-
BBH Market Vectors Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… s portfolio is much broader than that of BBH . The next-largest biotech ETF is SPDR ..... based in the U.S. comprise 96.5% of BBH 's assets. The remaining assets are invested ..... Suitability Market Vectors Biotech ETF BBH is an exchange-traded fund that offers …
-
IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… Biotech XBI and Market Vectors Biotech ETF BBH charge just 0.35%. Still and all, we ..... 0.63%), and Market Vectors Biotech BBH (0.35%). Both XBI and FBT offer equal ..... and Biogen Idec BIIB). As a result, BBH 's portfolio of 25 biotech stocks has an …